MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region (MT-RNR1). Foundational studies show that it can alter cellular metabolism, engage AMPK-linked signaling, and translocate to the nucleus during metabolic stress. In animals, exogenous MOTS-c has produced striking metabolic and performance effects. In humans, however, the evidence is mostly observational, exercise-physiology work, and one early clinical program involving CB4211 — a modified MOTS-c analog, not native MOTS-c.
The useful signal is therefore mechanistic, not promotional: interesting biology, meaningful preclinical data, and an unresolved translation gap.
What MOTS-c is
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was reported in 2015 as a mitochondrial-derived peptide encoded within a short open reading frame in the mitochondrial MT-RNR1 gene. That makes it part of a small class of mitochondrial-derived peptides involved in communication between mitochondrial state and broader cellular regulation.
The AMPK story is real — but not the whole story
The original metabolic work linked MOTS-c to disruption of folate-dependent purine metabolism, accumulation of AICAR-related intermediates, and downstream activation of AMPK. AMPK is a central energy-sensing kinase that coordinates responses to low-energy states, including glucose handling and substrate utilization.
Later work added another layer: under metabolic stress, MOTS-c can move into the nucleus and influence nuclear gene expression in an AMPK-dependent manner, including antioxidant-response programs associated with NRF2.
Additional preclinical studies have explored effects on myostatin signaling, adipose thermogenesis, oxidative stress, and skeletal-muscle mitochondrial efficiency. A 2026 University of Copenhagen study found improved intrinsic mitochondrial bioenergetic performance in mouse skeletal muscle through PGC-1α/AMPK-dependent mechanisms; its direct intervention findings were still animal data, while the human exercise component did not establish the same treatment effect in people.
Native MOTS-c still lacks a therapeutic human trial
Human studies have detected endogenous MOTS-c and examined associations with age, metabolic disease, and exercise. Those studies help establish that the peptide exists in human physiology; they do not establish that administering native MOTS-c treats obesity, diabetes, aging, or exercise performance.
CB4211: the key clinical distinction
The most relevant interventional human data come from CB4211, a modified MOTS-c analog developed by CohBar. In Phase 1b, 23 adults with obesity and fatty liver were randomized and 20 completed end-of-treatment assessments: 11 received CB4211 and 9 placebo. The studied Phase 1b regimen was 25 mg once daily for four weeks.
The trial reported acceptable short-term tolerability, reductions in ALT and AST, a reduction in glucose, and a trend toward lower body weight. Importantly, both CB4211 and placebo groups had substantial reductions in liver fat from baseline, so the study did not establish a clean liver-fat treatment effect. It was also a sponsor-run early-phase trial and does not validate native MOTS-c.
What the evidence supports — and what it does not
| Claim | Evidence | Protokol X read |
|---|---|---|
| AMPK-linked metabolic signaling | Cell + Animal | Well-supported mechanistically; human therapeutic translation remains unproven. |
| Nuclear translocation under stress | Cell + Animal | Directly demonstrated in experimental systems and central to the mitonuclear signaling concept. |
| Obesity / insulin-resistance improvement | Animal | Strong rodent signal. Native MOTS-c has no placebo-controlled therapeutic human trial. |
| Exercise-capacity enhancement | Animal | Shown in mice. No human trial demonstrates that exogenous native MOTS-c improves performance. |
| Muscle preservation / myostatin reduction | Animal | Preclinical signal; no established human muscle-preservation effect. |
| Human metabolic treatment | Early Analog Data | CB4211 gives a preliminary signal, but it is a modified analog and the study was small and early-phase. |
| Anti-aging / lifespan extension | Speculative | Healthspan-related animal findings do not equal proven lifespan extension in humans. |
| “Bottled exercise” | Extrapolated | Marketing shorthand. Pathway overlap is not physiological equivalence. |
Current status matters
MOTS-c is not FDA-approved for any therapeutic use. FDA has identified significant safety-information gaps and peptide-characterization / immunogenicity concerns in the compounding context. In July 2026, MOTS-c-related bulk substances were discussed by FDA's Pharmacy Compounding Advisory Committee for possible inclusion on the 503A Bulks List. That review is not the same as drug approval.
MOTS-c is explicitly prohibited at all times under the WADA Prohibited List as an AMPK activator / metabolic modulator. Competitive athletes should treat this as a clear anti-doping restriction.
Field assessment
The mechanism is more interesting than the marketing. MOTS-c sits at a rare intersection: a mitochondrially encoded peptide that can influence cellular metabolism and nuclear gene programs. That is meaningful biology. But mouse performance, mouse weight loss, and pathway overlap with exercise are not interchangeable with proven human outcomes.
Mechanism before claims. Evidence before confidence.
Dose data belong in methods — not as a protocol
Published animal studies have used species-specific experimental doses and routes. CB4211 clinical development used controlled investigational dosing of a modified analog. Those figures describe study design; they do not establish a validated dose, cycle, reconstitution method, or administration protocol for native MOTS-c in humans.
For that reason, this brief intentionally does not provide reconstitution instructions or convert animal dosing into a do-it-yourself human regimen.
Selected primary and regulatory sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID 25738459.
- Kim KH, Son JM, Benayoun BA, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524. PMID 29983246.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. PMID 33473109.
- Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PMID 33554779.
- Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026;246:682-696. PMID 41520850.
- CohBar Inc. Phase 1a/1b CB4211 topline data and SEC clinical presentation, 2021.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee materials for MOTS-c-related bulk drug substances, July 23, 2026.
- World Anti-Doping Agency. 2026 Prohibited List.